Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status < 2.

- Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid
tumor

- Patient meets at least 1 of the following criteria:

- Disease progression despite standard therapies

- No standard therapies are available or such therapies are not anticipated to
result in a durable response

- Standard therapies are considered unsuitable or have been refused

- Life expectancy > 12 weeks

- Able to be hospitalized from 1 day prior to the initial dosing until day 15 of the
dosing, and from day 27 until day 29 of the dosing

Exclusion Criteria:

- Patient exhibits persistent subjective and objective findings of toxicity ≥ Grade 2
(CTCAE v4.0-JCOG) from the previous cancer treatment with antitumor effect (except of
alopecias)

- Received previous treatment with antitumor effect within 21 days prior to the
scheduled initial dosing

- Patient had a major surgical procedure within 21 days prior to the scheduled initial
dosing or a major surgical procedure scheduled during the course of the study

- Use of an investigational drug or device within 21 days prior to the scheduled
initial dosing

- Use of blood transfusion or hematopoietic growth factors within 14 days prior to the
scheduled initial dosing

- A positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody
(anti-HCV)

- Known history of a positive test for human immunodeficiency virus (HIV) infection

- Patient has central nervous system (CNS) or leptomeningeal involvement with clinical
symptoms